Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.
Certain malignancies may possess a common and targetable matrix response, which affects disease pathogeneis, according to a study in Cancer Discovery.
New research examines the mechanisms underlying why most patients with high-grade serous ovarian cancer develop resistance to PARP inhibitors.
Optical coherence tomography and multispectral fluorescence imaging have demonstrated promising results in the early detection of ovarian cancer.
Researchers have developed a mouse model of high-grade serous carcinoma that could prove useful in the preclinical testing of prevention strategies for ovarian cancer.
Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.
Sorafenib combined with topotecan and then continued as maintenance therapy offered a significant improvement in survival outcomes in women with platinum-resistant ovarian cancer.
Apatinib combined with etoposide offers promising efficacy in patients with platinum-resistant ovarian cancer.
The regimen consisting of carboplatin and paclitaxel represents the backbone of ovarian cancer treatment. Here, we reflect on our experience administering the carboplatin/paclitaxel regimen to scores of ovarian cancer patients over the past decade and a half.
A murine study suggests this engineered combination may offer a major advantage over current CAR T-cell–based immunotherapies.